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Background. Although the patients with diagnosed B-NHL are classified into the same dis-
ease stage on the basis of clinical, histopathological, and immunological parameters, they
respond significantly different to the applied treatment. This points out the possibility that
within the same group of lymphoma there are different diseases at molecular level. For that
reason many studies deal with the detection of gene alterations in lymphomas to provide a
better framework for diagnosis and treatment of these hematological malignancies. Aim.
To define genetic alterations in the B-NHL with highest possibilites for diagnostic purposes
and molecular detection of MRD. Methods. Formalin fixed and paraffin embedded lymph
node tissues from 45 patients were examined by different PCR techniques for the presence
of IgH and TCR   gene rearrangement; K-ras and H-ras mutations; c-myc amplification
and bcl-2 translocation. There were 34 cases of B-cell non-Hodgkin’s lymphoma (B-NHL),
5 cases of T-cell non-Hodgkin’s lymphoma (T-NHL) and 6 cases of chronic lymphadenitis
(CL). The mononuclear cell fraction of the peripheral blood of 12 patients with B-NHL was
analyzed for the presence of monoclonality at the time of diagnosis and in 3 to 6 months
time intervals after an autologous bone marrow transplantation (BMT). Results. The
monoclonality of B-lymphocytes, as evidenced by DNA fragment length homogeneity, was
detected in 88 % (30/34) of B-NHL, but never in CL, T-NHL, or in normal PBL. Bcl-2
translocation was detected in 7/31 (22.6%) B-NHL specimens, c-myc amplification 9/31
(29%, all were more than doubled), K-ras mutations in 1/31 (3.23%) and H-ras mutations
in 2/31 (6.45%) of the examined B-NHL samples. In the case of LC and normal PBL, how-
ever, these gene alterations were not detected. All the patients (12) with B-NHL had domi-
nant clone of B-lymphocyte in the peripheral blood at the time of diagnosis while only  in 2
of 12 patients MRD was detected 3 or 6 months after BMT. Conclusion. Because it is quic
and simple, PCR analysis of clonal IgH rearrangements is very useful when diagnostic as-
sistance is required. This technique is also very effecient for tracking minimal residual dis-
ease in lymphomas and leukemias and for monitoring clonal evolution in acute and chronic
lymphoblastic leukemias and lymphomas. The presence of other genetic alterations, which
we detected, should serve as an additional prognostic or predictive factor in the patients
with B-NHL.
K e y   w o r d s :   lymphoma, non-Hodgkin; genetic phenomena; mutation;
polymerase chain reaction.
Introduction
Malignant lymphomas are a heterogeneous group of
B- or T-cell malignancies, which usually arise in lymph
nodes, but can also arise in any other organ in the body.
Their overall incidence, and the incidence of the various
histologic subtypes vary in different parts of the world. En-
vironmental exposures, viruses, chromosomal aberrations,
and congenital or acquired immunosuppression have been
associated with the development of lymphomas (1). Despite
these associations, the real cause of the majority of lym-
phomas remains unknown.
The diagnosis of lymphoma is usually based on mor-
phologic evaluation supplemented by the analysis of immu-       88                              2
nological markers. However, in some diagnostic categories
defined in this sense, the response of patients to treatment is
markedly heterogeneous, arising the suspicion that there
should be several molecularly distinct diseases within the
same morphologic category. For that reason many studies
deal with the detection of gene alterations in lymphomas to
provide a better framework for the diagnosis and the treat-
ment of these hematologic malignancies (2). Lymphomas
could be very difficult to distinguish from reactive lesions,
especially at the early stages of development, even with the
aid of immunophenotyping. The discovery of immunoglobu-
lin (Ig) gene rearrangements and the application of molecular
probes for these genes were confirmed as suitable to demon-
strate monoclonality, assign a disorder to either B- or  T-
lymphocyte lineage, and enable the detection of a small num-
ber of neoplastic cells. Until recently, this was carried out by
a time-consuming, complex Southern blot analysis of restric-
tion fragments which required relatively large amount of
heavy DNA extracted from fresh/fresh-frozen tissue or cell
suspensions (3). These limitations were overcome by the ap-
plication of Polymerase chain reaction (PCR) techniques (4,
5). The rapid clonality analysis of almost any clinical sample
could be carried out by PCR amplification of randomly as-
sembled different variable (V), sometimes diversity (D), and
joining (J) gene segments of antigen receptor genes.
Most of the patients suffering from hematologic malig-
nancies achieved a complete clinical remission (CCR) after
the conventional chemo- and radiation therapy-programs. The
introduction of allogenic and autologous bone marrow trans-
plantation (BMT) in treatment protocols further increased the
remission rates in lymphomas and leukemias. However, a sig-
nificant proportion of patients that achieved a CCR, relapsed
and died from their primary disease (lymphoma or leukemia)
or complications of a subsequent therapy. It is believed that a
disease recurrence is caused by a few malignant cells not
eradictaded with the induction therapies. The level of disease
undetectable by conventional cytomorphologic methods, is re-
ferred to as the minimal residual disease (MRD). PCR tech-
niques can be used for the detection of tumor-specific se-
quences, such as the junction regions of rearranged immuno-
globuline (Ig) and T-cell receptor (TCR) genes, the break-
point fusion of the regions of chromosome aberrations and
mutations in tumor suppressor genes and oncogenes (6). In
that way, the sensitive PCR-based techniques for detection of
clonally rearranged immune genes might become useful and
broadly applicable diagnostic tools for the monitoring of the
patients with B- and T-cell malignancies (7).
In this study, we considered not only the clonality
analysis, but also the incidence of K- and H-ras mutation, c-
myc amplification and bcl-2 translocation in B-cell non-
Hodgkin’s lymphoma. These genes were included in the
study because their products are involved in the regulation
of cell cycle, proliferation and programmed cell death.
Ras proteins are localised to the inner face of the
plasma membrane and specifically bound to guanine nu-
cleotides-guanosine diphosphate (GDP) and guanosine tri-
phopate (GTP)- with high affinity and specificity. The abil-
ity of ras to alternate between inactive (GDP-bound) and
active (GTP-bound) forms is a major determinant of cell
growth and proliferation. The transforming activity of ras
oncogenes in human tumors is a consequence of point mu-
tations, most often in codons 12, 13, and 61, resulting in
single amino acid substitutions. The point mutations that
convert ras into an oncoprotein alter its interactions with
guanine nucleotides so as to maintain the ras protein in the
constitutively active GTP-bound state (8).
The members of myc gene family   c-myc, N-myc,
and L-myc   have neoplastic potential, and are activated as
oncogenes in a wide variety of neoplasms as a consequence
of the most frequent chromosome translocation or amplifi-
cation (9). The c-myc gene codes for c-myc protein which is
a transcription factor that is located in the cell nucleus,
where myc functions to modulate gene expression in re-
sponse to the proliferative stimuli. Elevated myc expression
stimulates or represses transcription of its target genes by
increasing the formation of c-myc/max heterodimers, con-
sistent with the frequent activation of myc oncogenes by
genetic alterations that result in myc overexpression (10).
The bcl-2 family of related proteins is a part  of an im-
portant control mechanism for the regulation of apoptosis.
There are over a dozen members in the family, some of which
suppress apoptosis, including bcl-2 and bcl-xL, and others
which promote it, such as bax and bak. The bcl-2 is a proto-
typic family member localised to the outer mitochondrial
membrane, and also to endoplasmic reticular and outer nu-
clear membranes (11). The bcl-2 protein inhibits apoptosis in-
duced by a variety of stimuli in many cell types, suggesting
that bcl-2 is an integral, possibly central, player in cell sur-
vival programmes. The bcl-2 gene was originally found in a
proportion of B-cell follicular lymphomas at the t(14; 18)
chromosomal translocation breakpoint (12). In these translo-
cations, bcl-2 gene is moved from its normal location on
chromosome 18q21 into juxtaposition with the IgH locus on
chromosome 14q32, which leads to increased expression of
the normal bcl-2 protein. Selective overexpression of bcl-2 in
the lymphoid system produces B-cell lymphoma, where pro-
gression to high-grade lymphoma often coincides with c-myc
translocation (13). Overexpression of bcl-2 is found in many
types of tumors, including the majority of breast carcinomas
(14, 15), and has been shown to cooperate with c-myc and ras
(16) family members during cellular transformation.
The aim of this study was to define the incidence of
genetic alterations in non-Hodgkin’s lymphoma and  re-
spectively evaluate their diagnostic potential and usefulness
for the traciking of minimal residual disease (MRD). For
that purpose, PCR-SSCP analysis was used to investigate
the presence of point mutations in codons 12 and 13 (exon
1) of K- and H-ras oncogenes; the amplification of c-myc
oncogene was analyzed using “differential” PCR; the pres-
ence of translocation t (14; 18) of bcl-2 oncogene was ana-
lyzed by the “nested” PCR; the rearrangement of gene cod-
ing of IgH was analyzed by “touch down” PCR; and the re-     2                                89
arrangement of variable region of gene coding for   chain of
TCR was analyzed by “multiplex” PCR.
Methods
Patients and specimens
Formaldehyde fixed and paraffin embedded lymph
node tissues from 45 patients were examined. There were
34 cases of B-cell non-Hodgkin’s lymphoma (B-NHL), 5
cases of T-cell non-Hodgkin’s lymphoma (T-NHL) and 6
cases of chronic lymphadenitis (CL). All patients were
treated at the Clinic for hematology, Military Medical
Academy Belgrade, and their diagnoses were established
according to clinical parameters and routine histologic, im-
munohistochemical and immunophenotypic methods. The
mononuclear cell fraction of the peripheral blood (PBL) of
7 healthy persons was also examined.
The PBL of 12 patients with B-NHL was also analysed
for the presence of monoclonality at the time of diagnosis
and at 3 to 6 months time intervals after an autologous bone
marrow transplantation (BMT).
DNA extraction
Paraffin-embedded tissue was deparaffinized by xylol,
followed by two ethanol washes. The mononuclear cell
fraction of the peripheral blood was obtained by Lympho-
prep centrifugation (Nycomed Pharma, Norway). The sam-
ples were then lysed in the digestion buffer, containing 100
mmol/l NaCl, 10 mmol/l Tris-Cl, 25 mmol/l EDTA; pH 8.0,
0.5% SDS and 0.1 mg/ml proteinase K (USB, USA). The
samples were incubated for 24 hours at 37 
oC. DNA was
isolated by standard phenol-chloroform extraction, and pre-
cipitated with 1/10 of volume 7.5 mmol/l ammonium-
acetate and 2.5 of volume cold absolute ethanol, recovered
with centrifugation at 15000  g for 10 minutes at 4 
oC, and
resuspended in 100 μl double distilled water  (17).
PCR amplification of oncogenes
The sequences of primers for codons 12 and 13 of the
K- and H-ras oncogenes were as follows: K-ras (s)
ATGACTGAATATAAACTTGT and  (as)
CTCTATTGTTGGATCATATT; and H-ras (s):
ATGACGGAATATAAGCTGGT and (as):
CGCCAGGCTCACCTCTATA. The initial denaturation
took 5 minutes at 95 
oC, and each mixture was then sub-
jected to 35 cycles of amplification, each of which included
a denaturation step at 94 
oC for 1 minute, an annealing step
at 58 
oC for 1 minute (H-ras), and at 50 
oC for 1 minute (K-
ras), and an elongation step at 72 
oC for 1 minute.
To study the presence of c-myc amplification we used
the differential PCR. The differential PCR assays involved
simultaneous amplification of two target sequences in the
same tube, with the relative amount of the two PCR prod-
ucts indicating the relative gene dosages. We used the prim-
ers for c-myc gene and D2R gene (dopamine D2 receptor,
control gene present in one copy in human genome), which
yielded products of 150 base pairs (bp) and 110 bp, respec-
tively. The sequences of primers for c-myc gene were: (s):
GCTCCAAGACGTTGTGTGTTCG, (as) :
GGAAGGACTATCCTGCTGCCAA  and D2R (s):
CCACTGAATCTGTCCTGGTATG, (as):
GTGTGGCATAGTAGTTGTAGTGG. The PCR protocol
included starting denaturation followed by 27 cycles of 1
minute each at 94 
oC, 50 
oC, and 72 
oC, respectively.
Polyacrylamide gel electrophoresis of the differential
PCR products demonstrated two discrete bands of the pre-
dicted size (c-myc = 150 bp, D2R = 110 bp). The c-myc
copy number was estimated by comparing the relative in-
tensity of c-myc and D2R receptor bands. The band intensi-
ties were quantitated by scanning densitometry which
yielded two peaks (one for c-myc, and another for D2R),
together with data about peak heights and relative areas,
which were obtained by integrating the peaks, and which
were directly proportional to concentration of amplified
DNA. To control D2R gene, which was a referent amount
in each sample, the relative area of the band was 100%.
Thus, there was an internal control in each sample, and
relative areas obtained for c-myc band were presented with
reference to that control (c-myc/D2R).
The translocation t(14; 18) of bcl-2 oncogene was
analyzed using the nested PCR  with two sets of primers
specific for the MBR region of bcl-2 gene and JH region of
IgH (18 ). The product of the first PCR reaction was ream-
plified by the second PCR reaction using the second set of
primers internal to the primers used for the initial amplifi-
cation, which increased the specificity of the reaction. The
product of the second reaction was 140 250 bp long.
The starting denaturation was followed by 25 cycles of
the initial amplification. The reamplification of a 5- l ali-
quot of the amplified mixture was performed in 30 cycles
using primers internal to the original ones, with 1 minute of
denaturation at 94 
oC, annealing at 58 
oC, and of extension
at 72 
oC.
PCR amplification of 3 frameworks of CDR region
IgH gene (B clonality)
The rearrangement of the genes encoding of IgH
(framework regions I, II and III) was analyzed using the touch
down PCR (19, 20). That PCR increased specificity of the re-
action. In the first cycle of PCR, the temperature was by sev-
eral degrees higher than it was optimal for annealing (60 
oC),
which reduced nonspecific binding of primers to DNA tem-
plate at the beginning of the reaction. The annealing tem-
perature decreased gradually to the optimal value (56 
oC), and
remained unchanged in the succeeding cycles. The amplified
fragments were 100 150 bp long.
PCR amplification of   chain T-cell receptor gene (T
clonality)
The variable region rearrangements of the genes en-
coding of the   chain of the T-cell receptor were analyzed
using multiplex PCR (21). The multiplex PCR used numer-       90                              2
ous primers, in this case 5 primers for V and 3 primers for J
gene regions, which enabled simultaneous amplification of
several sequences. The amplified fragments were about 200
bp long.
All PCR amplifications were performed in (Mastercy-
cler gradient, Eppendorf, Germany) a 50 μl final volume
using 400 600 ng of genomic DNA, 0.4 μmol/l of primers
(Applied Biosystems, 380B DNA Synthesizer), 250 μmol/l
each of dNTP (Applied Biosystems), 1.2 U Taq polymerase
(Applied Biosystems) in 1xPCR buffer with 15 mmol/l
MgCl2 (Applied Biosystems).
For the identification of amplified products (bcl-2 and
c-myc oncogenes, as well as rearranged antigene receptor
genes) we used 10% vertical polyacrylamide gels in 0.5 x
TBE buffer (45 mmol/l Tris-borate, 1 mmol/l EDTA)
(LKB, Pharmacia). The gels were stained with silver nitrate
(Serva). A DNA molecular weight marker (PCR Markers,
Promega) was used to provide a size estimation in base
pairs. A PCR fragment was considered to be monoclonal
only if one or two discrete narrow bands were observed
within the appropriate size range expected for a particular
primer pair. For FRI expected size range was 300 400 bp,
for FRII 240 260 bp and for FRIII 100 150 bp.
Point mutations of K- and H-ras oncogenes, codons 12
and 13 (exon 1), were detected using SSCP (single stranded
conformational polimorphism) method on silver stained
10% polyacrylamide gels.
To quantify the products of differential PCR for c-myc
and control D2R gene, the scanning densitometry was used
(LKB UltroScan XL, Sweden).
Results
DNA samples extracted from formalin fixed, paraffin
embedded lymph nodes from 34 cases of B-NHL, as well as
5 cases of T-NHL, 6 cases of CL and the mononuclear cell
fraction of the peripheral blood (PBL) of 7 healthy persons
were examined for immunoglobulin heavy chain gene rear-
rangement by polymerase chain reaction in order to com-
pare the efficiency of the chosen primers. The IgH rear-
rangements were considered to be of tumor origin if the
PCR product was predominantly monoclonal in at least two
amplifications. The primer sets showed different efficien-
cies in the amplification of monoclonal B-cell populations
(Table 1).
The amplification of genomic DNA with VH1/JHa
primer pair produced monoclonal pattern only in 8/34 cases
of B-NHL, while a smear of amplified DNA was found in
all other examined samples. In the second pair from FRI
(VH3/JHa), however, the monoclonal pattern was found in
25/34 B-NHL. A clear dominant band 100 150 bp in length
was seen in 30 of 34 studied  B-NHL, and in none of  5 T-
NHL, 6 CL and in all normal PBL’s when primers for FRIII
were used. In the case of negative results, i.e. when lym-
phocyte population was polyclonal, a diffuse smear or many
discrete bands were found. Examples of the findings are
shown in Figure 1. The same samples (except CL) were ex-
amined for the presence of K- and H-ras (codons 12 and 13)
point mutations, amplification of c-myc and translocation
t(14;18) of bcl-2 (Table 2).
K-ras point mutations were found in 2 of 31 case of B-
NHL (6.45%), whereas H-ras point mutations were found in
only 1 of 31 case of B-NHL (3.23%) (Figure 2). No point
mutations in K- and H-ras were found in all other patients
and healthy persons.
Using differential PCR with two sets of primers for the
c-myc and control gene, dopamine D2 receptor (D2R), ac-
cording to c-myc/D2R ratio patients were divided in three
groups. The first group contained the patients with c-
myc/D2R ratio < 100%, the second group 100 200%, and
the third group > 200%. Nine patients from the third group
(c-myc/D2R ratio > 200%) had a double or higher c-myc
amplification compared with the D2R gene, and were
treated as positive. No amplification was detected in any
other patients and healthy persons (Figure 3).
Table 1
Distribution of B-cells clonality detection rates among different primer pairs
                                              Primer pairs Diagnosis
VH1/JHa VH3/JHa VH4a/JHa FRIIa/JHb FRIII/JH TcR
B-NHL 8/34 25/34 15/34 12/34 30/34 0/5
T-NHL 0/5 0/5 0/5 0/5 0/5 5/5
CL 0/6 0/6 0/6 0/6 0/6 0/6
PBL 0/7 0/7 0/7 0/7 0/7 0/7
Table 2
Distribution of gene alterations among different
non-Hodgkin
’s lymphomas
Gene alterations Diagnosis
H-ras K-ras bcl-2 c-myc
B-NHL 1/31 2/31 7/31 9/31
T-NHL  0/5  1/5
PBL 0/7 0/7 0/7 0/7     2                                91
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Fig. 1   Detection of B-cell clonality in patients with B-NHL.
Lanes 1, 2, 3 and 4 have dominant clone of B-lymphocytes,
while in lane 5 we have detected polyclonal smear. Lane 6 is
molecular weight marker (in base pairs).
       1         2             3
Fig. 2   Detection of H-ras point mutations in
lymph nodes of patients with B-NHL by PCR-SSCP
method on 10% polyacrylamide gel (silver stained).
Lane 2   negative sample; Lanes 1 and 3   positive samples.
   1      2       3       4       5
c-myc
D2R
Fig. 3   Detection of c-myc oncogene amplification in lymph
nodes of patients with B-NHL by differential PCR. C-myc was
amplified in all samples.
The clonality of T-cells was detected by the multiplex
PCR, with 5 primers for V and 3 primers for J variable re-
Translocation t(14;
18) of bcl-2 was
detected in 7 of 31
cases of B-NHL
(22.6%) (Figure 4).
This translocation
wasn’t found in any
other patients and
healthy persons.
72
118
194
 1        2       3       4     5        6 7
Fig. 4   Detection of
t(14;18) translocation
of bcl-2 oncogene in
lymph nodes of pa-
tients with B-NHL.
Lanes 3, 4 and 5  
negative samples; lanes
6 and 7   positive sam-
ples. Lane 1   molecular
weight marker (in base
pairs) and lane 2   
negative control of PCR
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gion gene segments coding for  -chain of TCR. The pres-
ence of dominant T-cell clone was detected in all the cases
of T-NHL, whereas all other patients and healthy persons
were TCR   negative.
In order to evaluate the usefulness of two primer pairs
(VH3/JHa and FRIII/JH ) for molecular detection of MRD in
12 patients with B-NHL, the presence of a dominat clone, in
the peripheral blood was examined before, and after an
autologous bone marrow transplantation. In all the patients
included in this study the presence of dominant clone was
detected in the peripheral blood at the time of diagnosis. In
3 6 months after transplantation the dominant clone was
detected in 2 patients, while in other patients polyclonal
pattern was found.
Discussion
Numerous IgH-CDR3 PCR-based techniques were de-
scribed, but NHL specimens often contain the significant
number of the non-neoplastic B cells in addition to the ma-
lignant B cell clone. Thus, a mixture of unrelated IgH-CDR3
junctions is usually amplified by PCR, together with clonal
IgH-CDR3 junctions giving sometimes false negative re-
sults (22).  Moreover, they occur as a result of somatic mu-
tations or deletion of the specific region (22; 6). Although
the amplification of FRIII/JH was preferred as the products
were small and therefore more readily amplified from de-
graded samples and easier resolved by electrophoresis it
seemed that it was necessary to use more than one pair of
primers and to establish the strict criteria for the definition
of monoclonality in order to minimize the probability of
false positive and negative results (23, 24). Therefore, in
this study we also used primers from FRII and three pairs of
primers from FRI because it was helpful in the cases when
FRIII primers failed to bind, although they required the
template DNA of a reasonably good quality to allow for the
longer PCR products (about 250 bp for FRII and 350 bp for
FRI as compared to 120 bp when primers for FRIII were
used). For that purpose we chose the panel of primer se-
quences with high sensitivity and specificity (20, 24, 25).
The best results in detection of monoclonality were ob-
tained when we used primers for FRIII. The monoclonality
of B-lymphocytes, as evidenced by DNA fragment length
homogeneity, was detected in 88% of B-NHL, but never in
T-NHL, CL or in normal PBL. Our results  suggest that the
clonality analysis of IgH gene rearrangement is reliable
when using paraffin-embedded samples in approximately
70 80% cases (6, 26) of the B-cell lymphomas, confirming
the diagnostic potential of the technique. Recent reports
suggest that up to 96% of the low grade B-cell, non-
follicular lymphomas and 82% of high or intermediate
grade lymphomas could be amplified using multiple primers
(6, 22). In our study low- and high-grade lymphomas were
included, and using 5 pairs of primers we succeed in de-
tecting monoclonality in all cases, although paraffin embed-
ded samples were used. The primers from FRI (VH3/JHa),
compared to the primers from FRIII, were more sensitive
(73%) in detection of monoclonality and when used to-
gether 91% of the cases were defined as monoclonal. We
believe that additional use of VH3/JHa primers could be
valuable in some cases when the discovery of monoclonal-
ity is doubtful and when fresh or fresh/frozen samples are
used.
The finding of three clonal PCR products indicates
that more than one B-cell clone is present (27). Such oligo-
clonal rearrangements are detected in the rare cases of fol-
licular center cell-derived lymphomas and in 15 to 45% of
the patients with acute lymphoblastic leukemia (ALL) (28).
The oligoclonality of B-cell ALL is caused by ongoing VH
gene rearrangement reflecting recombinase activity in an
immature leukemic clone (4). The presence of clonally re-
lated and yet diverse population of leukemic blasts is clini-
cally significant as these clones may in time predominate
and compromise the ability to detect minimal residual dis-
ease at the molecular level (28, 29).The detection of clonal
IgH rearrangements by PCR has an advantage over South-
ern blot procedure since only the complete VDJ rearrange-
ments will be amplified enzymatically, but not the incom-
plete rearrangements or rearrangements resulting from
chromosomal translocations involving the IgH gene locus.
Because of its speed and simplicity, the PCR analysis has
priority when diagnostic assistance in a difficult case is re-
quired (30). But, it should be kept in mind that molecular
test results have to be considered in the context of morphol-
ogy and immunohistochemistry. The detection of a clonal
lymphocyte population in clinical samples is usually ab-
normal but it should not be considered as a proof of malig-
nancy.
This technique is very efficient in tracking minimal re-
sidual disease in lymphomas and leukemias (31, 32) and in
monitoring clonal evolution in acute and chronic lympho-
blastic leukemias and lymphomas (33) as well as in detect-
ing clonal rearrangements of T-cell receptor for differential
diagnosis and monitoring of T-cell lymphoma (21, 34). The
use of CDR3 as clonal marker of multiple myeloma showed
an excellent sensitivity as it was demonstrated that circu-
lating malignant cell could be identified in the majority of
patients with the frequency of 0.001% to 1% (24, 35). Our
study included 12 patients with B-NHL who had the domi-
nant clone of B-lymphocites in the peripheral blood at the
time of diagnosis. Those patients were treated with autolo-
gous BMT and within the first 3 to 6 months after BMT
were tested for the presence of dominant clone in PBL. In
2/12 patients the dominant clone was found and one of the
patients died while the other one remained in stable remis-
sion. In the group of patients (10 pts) without the presence
of dominant clone in PBL, four patients developed relapse,
while other six were in remission. These results were in
compliance with the findings that detection of residual dis-
ease on molecular level cannot be interpreted in one way,
i.e. some investigators found that detection of residual dis-
ease immediately following induction or during the first 6     2                                93
months predicts likelihood of relapse, others reported that
MRD can persist for 24 months and even longer. Our results
and the results of other authors underline the impor-
tance/necessity of the serial assessments and quantification
of MRD (36).
The members of ras proto-oncogenes were present in
a variety of human malignancies, and are among the most
frequent genetic aberrations detected in human tumors
(acute myeloid leukemias 25%; colon carcinomas 50%;
lung carcinomas 25%; and pancreatic carcinomas 90%).
The mutations of N- and K-ras genes are the most fre-
quent genetic aberrations in acute myeloid leukemia
(AML) and their detection under preleukemic conditions
such as the myelodysplastic syndrome (MDS) suggests
their significance for the earliest stages of leukemogenesis
(37). Despite these observations, our results show that ras
mutations are rare event in B-NHL and also suggest that
their presence could serve as an additional factor in the
assessment of tumor biology in individual patients with
NHL.
We found that almost one third of B-NHL (29%) has a
significant amplification of the c-myc gene. Although our
method for measaurement of gene amplification is semiqua-
nitative, it implies that the more precise measurement of c-
myc amplification (38) can provide better understanding of
lymphoma cell biology. Normally, c-myc expression is in-
duced during cell proliferation after the action of a mito-
genic stimulus or is suppressed by the action of factors
which arrest the cell in the G1 stage of the cell cycle. Obvi-
ously, c-myc has a dual role: (a) to promote proliferation in
the presence of a relative abundance of the appropriate
growth factors; and (b) to induce apoptosis when c-myc is
expressed in cells during the growth arrest (39). The expres-
sion of bcl-2 gene in pre-B cells of transgenic mice with a
high expression of c-myc promotes survival of these cells,
meaning that bcl-2 cooperates with c-myc to immortalize
pre-B cells (13).
The translocation of bcl-2 oncogene was detected in
7/31 cases, and 6 were low grade lymphoma and 1 high
grade. Bcl-2 oncogene was first identified as a gene overex-
pressed in human follicular B-cell lymphomas, following
reciprocal chromosomal translocation t(14; 18). When over-
expressed, bcl-2 inhibits apoptosis in a variety of cells. The
bcl-2 and bax protein products can form homodimers or
heterodimers. The bax gene has an antagonizing effect on
bcl-2 and it is a key effector gene of the p53 gene in the in-
duction of apoptosis. The bcl-2 cooperates with deregulated
c-myc expression to promote hematopoetic tumor develop-
ment in transgenic mice. Since bcl-2 inhibits the induction
of apoptosis by c-myc, the basis of this cooperation is pre-
sumably the preservation from apoptosis by bcl-2 of c-myc
expressing target cells which then can proliferate (40, 41).
The deregulation of bcl-2 expression is in a relation with
the development of neoplastic transformation, and tumors
with high level of bcl-2 expression show an increased resis-
tance to different cytotoxic drugs routinely used in chemo-
therapy. Apart from its role in protecting against physiologic
cell death, bcl-2 renders cells resistant to radiation and to cy-
totoxic drugs, but CTL killing is not inhibited.  When bcl-2
translocation is found in PBL at the time of diagnosis it can be
further used as a molecular marker of MRD, especially in the
group of patients treated with monoclonal antibody  that re-
acts with the cell-surface protein CD20 expressed by normal
and malignant mature B-cells (42).
Clinical assessment and histology remain the “golden
standard" for evaluating hematologic malignancies and can-
cers in general. However, in the postgenomic era the new
goal is to asses the possibility to use molecular abnormali-
ties for diagnostic, prognostic and predictive purposses.
Some expectations go even further trying to define tumor
phenotype and to use this as a new golded standard for dis-
ease stageing and treatment (43, 44). Thus, in our study we
tried to define genetic alterations in B-NHL with the great-
est diagnostic potential for molecular detection of MRD.
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GENETSKE ALTERACIJE KOD NON-HODGKINOVIH LIMFOMA B- ELIJA
Uvod. Iako se, u zavisnosti od klini kih, patohistoloških i imunoloških parameta-
ra, bolesnici sa dijagnozom B-NHL svrstavaju u isti stadijum bolesti, oni zna ajno
razli ito reaguju na primenjenu terapiju. Ovo ukazuje na mogu nost da u okviru
iste grupe limfoma postoje razli ite bolesti na molekulskom nivou. Zbog toga
mnogi u svetu  izu avaju genske alteracije u limfomima sa ciljem da se definišu
bolji dijagnosti ki i prognosti ki parametri. Cilj ovog rada je bio da se definišu
genske alteracije u NH-limfomima koje se mogu koristiti u dijagnosti ke svrhe i
za otkrivanje minimalne rezidualne bolesti (MRB). Metode. Limfni  vorovi 45
bolesnika, ukalupljeni u parafin, iskoriš eni su za otkrivanje: rearanžmana gena
za IgH (teški lanac imunoglobulina), TCR-  ( -lanac T- elijskog receptora); mu-
taciju u K- i H-ras onkogenima; amplifikaciju c-myc i bcl-2 translokaciju uz pomo 
razli itih tehnika lan ane reakcije polimeraze (PCR). Analizovano je 34 B-ne
Hodgkinovih limfoma (B-NHL), 5 T-NHL i 6 slu ajeva hroni nog limfadenitisa
(CL). U perifernoj krvi 12 bolesnika sa B-NHL je u vreme dijagnoze, i 3 do 6 me-
seci nakon autologe transplantacije mati nih  elija hematopoeze, prona en je
dominantni klon B-limfocita. Rezultati. Monoklonost B-limfocita je otkrivena u
88% (30/34) B-NHL. Translokacija bcl-2 je otkrivena u 22,6% uzoraka (7/31), c-
myc amplifikacija u 29% (9/31, svi su amplifikovani više od 2 puta), K-ras muat-
cija u 3,23% (1/31), H-ras mutacija u 6,45% (2/31), kada se radilo B-NHL, dok u
slu aju T-NHL, CL i periferne krvi zdravih kontrola ove alteracije nisu otkrivene.
U perifernoj krvi svih bolesnika sa B-NHL je dokazano prisustvo dominantnog
klona B-limfocita u momentu postavljanja dijagnoze dok je nakon autologe tran-
slpantacije mati nih  elija hematopoeze kod samo dva bolesnika otkriven domi-       96                              2
nantni klon B-limfocita (u periodu od 3 do 6 meseci nakon transplantacije). Zak-
lju ak. U slu ajevima kada postoje sumnje u vezi dijagnoze B-NHL otkrivanje
rearanžmana gena za IgH uz pomo  PCR može biti izuzetno korisno zbog brzine
i jednostavnosti reakcije. Ova tehnika je korisna i za otkrivanje MRB kod limfoma
i leukemija, a može se koristiti za pra enje klonske evolucije kod istih bolesti.
Prisustvo ostalih genskih alteracije koje smo ispitivali može biti upotrebljeno  kao
dodatni prognosti ki ili prediktivni parametar.
K lj u   n e  r e   i :   limfom,  nehodžkinov;  genetski fenomeni; mutacija;
polimeraza, reakcija stvaranja lanaca.
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